ClearPoint Neuro Q3 2026 Earnings: Revenue Rises 36% as Loss Widens

ClearPoint Neuro (NASDAQ: CLPT) reported Q3 2026 revenue of $12.1 million, up 36% from $8.9 million a year earlier, while diluted EPS was a loss of $0.24 versus a loss of $0.21. Growth came from all three reported revenue categories, led by acquired IRRA flow products and higher capital placements, but gross margin contracted to 58% and net loss widened to $7.5 million. Cash and cash equivalents ended the September 30 quarter at $46.2 million after equity financing largely offset operating cash use through the first nine months.

Core Financial Results

Revenue increased by $3.2 million year over year. Although the 36% revenue gain exceeded the 23% increase in operating expenses, gross profit rose more slowly because gross margin fell by five percentage points.

Operating expenses remained above gross profit, resulting in a wider operating loss. Higher interest expense also contributed to the increase in the net loss.

Business and Segment Performance

Each reported revenue category grew, but the drivers differed. Neurosurgery navigation and therapy benefited primarily from IRRA flow, acquired with IRRAS in November 2025, while biologics and drug delivery growth came mainly from services performed at ClearPoint Advanced Laboratories.

Capital equipment and software reached a quarterly record, supported by increased placements of ClearPoint navigation hardware and software, IRRA flow control units, and Prism laser units. Because IRRA flow was not part of the company in the comparable quarter, the 59% growth in neurosurgery navigation and therapy should not be viewed as entirely organic.

ClearPoint also reported two development milestones. One partner submitted its first formal biologics license application for a Huntington’s disease treatment. Separately, ClearPoint is an industry partner in a five-year, $2.98 million NCI grant led by Dartmouth Health to advance MR-guided laser therapy for spinal metastases; the project remains early-stage research, and the full grant amount was not disclosed as ClearPoint revenue.

Revenue Growth Outpaced Expenses, but Losses Still Widened

Gross margin declined to 58% from 63%, primarily because of overhead at the new ClearPoint Advanced Laboratories facility and amortization of acquired intangible assets. Lower other cost-of-revenue items provided only a partial offset. This margin contraction meant that the 36% revenue increase produced only 26% growth in gross profit.

Operating expenses rose to $13.4 million. Research and development costs increased to $4.0 million from $3.5 million, sales and marketing expenses rose to $5.5 million from $3.8 million, and general and administrative expenses increased to $3.8 million from $3.6 million. The company attributed the increase mainly to the IRRAS acquisition, including expanded clinical and sales teams, occupancy costs, and travel.

Interest expense was another source of pressure, increasing to $1.4 million from $0.9 million. As a result, the net loss widened even though revenue grew faster than operating expenses.

Equity Financing Offset Operating Cash Use

ClearPoint ended the quarter with $46.2 million in cash and cash equivalents, compared with $45.9 million at the end of 2025. The nearly unchanged balance was supported by $22.0 million of net proceeds from the company’s at-the-market equity offering program.

For the first nine months of 2026, net cash used in operating activities was $20.1 million, up from $11.8 million in the prior-year period. The company also used approximately $1.0 million for capital expenditures, while financing activities provided $21.2 million.

Long-term notes payable increased to $50.8 million from $49.1 million at year-end. Common shares outstanding rose to 32.1 million from 29.4 million, an increase of approximately 9%, reflecting the role of equity issuance in maintaining liquidity.

2026 Revenue Guidance

ClearPoint now expects full-year 2026 revenue of $48.0 million to $50.0 million. With $35.1 million reported during the first nine months, reaching that range would require approximately $12.9 million to $14.9 million of fourth-quarter revenue.

The implied fourth-quarter range is an arithmetic calculation based on the annual outlook, not separately issued quarterly guidance. The source did not provide a prior full-year guidance range for comparison.

Recent Insider Transactions

The six-month summary showed 186,040 shares acquired across 17 transactions and 108,349 shares sold across five transactions, producing a net increase of 77,691 shares. However, the latest 10 records consisted of six stock awards, three derivative-security conversions, and one sale, so the activity should not be interpreted as 10 open-market purchases.

All 10 transactions were reported as direct holdings. The data does not support drawing conclusions about insiders’ views of the company’s valuation or outlook.

Risks Investors Need to Watch

• Gross-margin pressure: New laboratory overhead and acquired-intangible amortization reduced gross margin by five percentage points. Continued revenue growth may not translate into narrower losses unless margins recover or expenses grow more slowly.
• Operating cash use and equity issuance: ClearPoint used $20.1 million of cash in operations during the first nine months. The cash balance remained stable mainly because of $22.0 million in ATM proceeds, while shares outstanding increased by approximately 9% from year-end.
• Dependence on acquired-product growth: IRRA flow was the primary driver of the 59% increase in neurosurgery navigation and therapy revenue. Future performance depends partly on continued adoption and successful integration of the acquired portfolio.
• Partner and regulatory timing: Biologics and drug delivery revenue depends on customer-sponsored programs, while broader commercial opportunities are tied to clinical trials and regulatory decisions outside ClearPoint’s direct control.
• Debt and interest costs: Long-term notes payable reached $50.8 million, and quarterly interest expense increased by approximately 54%, adding pressure below the operating-income line.

Summary

ClearPoint Neuro delivered 36% revenue growth in Q3 2026, with contributions from IRRA flow, laboratory services, and capital equipment placements. That growth did not yet produce lower losses because gross margin contracted, operating costs increased, and interest expense rose. The company’s $46.2 million cash position was supported by equity financing, making margin recovery, operating cash use, dilution, and the revenue needed to reach the $48.0 million to $50.0 million annual outlook the main issues to monitor.